StreetInsider.com News Articles

Form 8-K TuHURA Biosciences, Inc. For: Oct 09

Fri, 16 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27198566.html

TuHURA Biosciences receives new U.S. patent for TBS-2025 antibody

Tue, 13 Oct 2026 07:47:05 -0400

TuHURA Biosciences, Inc. (NASDAQ: HURA) announced that the U.S. Patent and Trademark Office has issued Patent No. 12,760,104, titled "Anti-VISTA Antibodies and Uses Thereof," expanding intellectual property coverage for its VISTA-inhibiting antibody TBS-2025.

The patent covers TBS-2025 along with antigen-binding fragments, framework and Fc region modifications, and bispecific and multi-specific antibodies across all classes of human antibodies. It also covers use of the antibody as a single agent or in combination with radiotherapy, chemotherapy, targeted therapies, tyrosine kinase inhibitor therapies, and immune checkpoint inhibitors, including PD-1 inhibitors.

The patent extends coverage to methods of treatment beyond cancer, including autoimmune disease and infection.

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

Tue, 13 Oct 2026 07:45:00 -0400

Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodies

TAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. 12,760,104 entitled,

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

Tue, 13 Oct 2026 07:45:00 -0400

Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodies

TuHURA Biosciences receives U.S. patent for delta opioid receptor technology

Mon, 05 Oct 2026 07:45:41 -0400

TuHURA Biosciences, Inc. (NASDAQ: HURA) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,734,168, titled "Delta Opioid Receptor Antagonists Reprogram Immunosuppressive Microenvironment to Boost Immunotherapy," according to a company press release.

The patent, issued September 15, 2026, covers administering delta opioid receptor (DOR) antagonists to cancer patients and mediating immunosuppressive myelopoiesis. It is directed to the administration of DOR antagonists in subjects with cancer associated with DOR-expressing Myeloid Derived Suppressor Cells (MDSCs), as well as combination therapies for treating and preventing cancer and metastasis. The patent term runs through 2043, before any patent term extension.

The patent

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Mon, 05 Oct 2026 07:45:00 -0400

Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies

TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Mon, 05 Oct 2026 07:45:00 -0400

Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies

Form 8-K TuHURA Biosciences, Inc. For: Sep 21

Thu, 24 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260924/27102809.html

TuHURA Biosciences (HURA) Reiterates at Market Outperform by Citizens on TBS-2025 Development

Wed, 23 Sep 2026 04:45:26 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $9.00 price target on TuHURA Biosciences (NASDAQ: HURA).

The analyst commented, "TuHURA is developing TBS-2025, a VISTA-inhibiting mAb in AML, rather than in solid tumors, where this checkpoint may be driving acquired resistance, especially in NPM1- mutated AML. TuHURA (Kineta) designed TBS-2025 to address shortcomings that have plagued prior VISTA mAbs that were developed in solid tumors: 1) longer half-life enables Q2W dosing with optimal receptor occupancy; and 2) improved alignment with VISTA biology, expanding the previously constrained therapeutic window, driven by cytokine release syndrome (CRS). The trial covers a large

Form 8-K TuHURA Biosciences, Inc. For: Sep 14

Thu, 17 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260917/27076657.html

Form 8-K/A TuHURA Biosciences, Inc. For: Sep 10

Thu, 17 Sep 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260917/27073547.html

Form 8-K TuHURA Biosciences, Inc. For: Sep 10

Wed, 16 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260916/27071024.html

TuHURA Biosciences gets FDA clearance to trial AML antibody

Mon, 14 Sep 2026 07:46:06 -0400

TuHURA Biosciences, Inc. (NASDAQ: HURA) announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application for TBS-2025, a VISTA-inhibiting monoclonal antibody, allowing a Phase 1b clinical study to proceed in patients with certain blood-related cancers.

The FDA's "Study May Proceed" notice permits TuHURA to evaluate TBS-2025 as a monotherapy at varying doses in patients with relapsed or refractory mutNPM1 Acute Myeloid Leukemia (AML) who have not responded to or have relapsed after menin inhibitor therapy. The company said patients in this category currently have no approved or effective treatment options.

The Phase 1b study will initially

TuHURA Biosciences gets FDA clearance to trial AML antibody

Mon, 14 Sep 2026 07:46:06 -0400

The Phase 1b study will initially

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Bloo

Mon, 14 Sep 2026 07:45:00 -0400

TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Bloo

Mon, 14 Sep 2026 07:45:00 -0400

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 07:45:00 -0400

TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY.

H.C. Wainwright 28^th Annual Global Investment Conference

Date:

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 07:45:00 -0400

H.C. Wainwright 28^th Annual Global Investment Conference

Date:

Form SCHEDULE 13D/A TuHURA Biosciences, Inc. Filed by: Bianco James A.

Fri, 28 Aug 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26999265.html

Form SCHEDULE 13D/A TuHURA Biosciences, Inc. Filed by: Bianco James A.

Fri, 28 Aug 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26999265.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 20

Fri, 21 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962307.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 20

Fri, 21 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962307.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 18

Wed, 19 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260819/26950949.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 18

Wed, 19 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260819/26950949.html

TuHURA Biosciences (HURA) Reiterated at Market Outperform by Citizens

Tue, 18 Aug 2026 04:15:50 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $9.00 price target on TuHURA Biosciences (NASDAQ: HURA).

The analyst commented, "TuHURA is focused on several novel approaches based on myeloid biology as well as a legacy product in Phase 3 development. Development of IFx-2.0 is ongoing and HURA has an aligned with the FDA on a path to the market that includes the potential to reach the market without a confirmatory study, based on PFS data of the Phase 3. TuHura's next-generation assets focus on a novel approach to AML, via targeting of immunosuppresive phenotype and reprogramming of the TME.